Guillaume Aussedat

Guillaume Aussedat

Auto-generated profile, based on publicly available information

Guillaume Aussedat

Department of Hematology, Hôpital Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon 1

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GAGuillaume Aussedat
Guillaume Aussedat
ATAlexandra Traverse‐Glehen
Alexandra Traverse‐Glehen
ASAspasia Stamatoullas
Aspasia Stamatoullas
TMThierry Molina
Thierry Molina
VSViolaine Safar
Violaine Safar
CSClementine Sarkozy
Clementine Sarkozy

31 October 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
GAGuillaume Aussedat
Guillaume Aussedat
DMDelphine Maucort-Boulch
Delphine Maucort-Boulch
PRPhilippe Rey
Philippe Rey
VSViolaine Safar
Violaine Safar
LKLionel Karlin
Lionel Karlin
HGHervé Ghesquières
Hervé Ghesquières
We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m2) in combination with etoposide (300 mg/m2) and ifosfamide (1500 mg/m2) at 2, 3, or 4-week intervals. Median age was 79 years (range, 64–92). The median number of previous line was 1 (range 1–8). Patients received a median of six cycles (1–12). Fourteen patients (19%) presented partial and 14 complete responses (19%). Among the 369 cycles, nine patients developed febrile neutropenia (13%), 14 a grade 3–4 neutropenia (19%), 7 a grade 3–4 thrombocytopenia (10%) without grade 3–4 non-hematological toxicity. With a median follow up of 7.8 months, the median progression-free survival, overall survival, and duration of response were 4.4 months, 9.4 months, and 12 months, respectively. This regimen represents a therapeutic option in R/R DLBCL patients ineligible to ASCT.